No Detail Found!

Efficacy and safety of omalizumab in the treatment of chronic urticaria: A case series

Author(s)
Asif Kamal Department of Dermatology,Islamabad Medical Complex, NESCOM, Islamabad, Pakistan
Maryum Nouman Department of Dermatology,Islamabad Medical Complex, NESCOM, Islamabad, Pakistan
Abstract
Chronic idiopathic urticaria (CIU) is a disease with significant impact on the quality of life owing to its morbidity and relative high prevalence. Omalizumab is a recombinant monoclonal antibody against IgE that inhibits binding of IgE to FceRI on the cell surface of mast cells. Its role has been thoroughly studied in asthma. We present a case series focusing on the role of subcutaneous omalizumab in the treatment of CIU along with its safety profile in terms of immediate and late side effects.
Publication Details
Page(s) 282-285
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 27, Issue: 3, Year: 2017

Request the full text from PASTIC

Keywords
Chronic idiopathic urticaria, Omalizumab
0

Citations

0

Downloads

90

Views